Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis
NCT02718677 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2020-11-16
Summary
This NIS aims to assess the patient-reported outcomes (PROs) in enrolled subjects
Conditions
Interventions
- DRUG
-
Refacto AF
Observational - Non-Interventional Study
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 2 Years
- Max Age
- 30 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-01
- Primary Completion
- 2021-05-01
- Completion
- 2022-01-01
- FDA Drug
- Yes
More Related Trials
-
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
NCT00157053 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
NCT00157157 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A
NCT01454739 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study
NCT02740413 ·Status: COMPLETED
-
Study Evaluating Refacto For Pharmacovigilance
NCT00195442 ·Status: COMPLETED
-
Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings
NCT00884390 ·Status: TERMINATED ·Phase: PHASE4
-
Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
NCT00038935 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
NCT00157105 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A
NCT00157040 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B
NCT01425723 ·Status: COMPLETED ·Phase: PHASE3
-
Post-marketing Surveillance (Use Result Surveillance) With Refixia®
NCT03875547 ·Status: COMPLETED
-
Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
NCT02392156 ·Status: TERMINATED
-
Prophylaxis Regimen for Hemophilia A Patients
NCT05036278 ·Status: COMPLETED ·Phase: PHASE4
-
Factor Product Utilization and Health Outcomes in Patients With Hemophilia
NCT02796222 ·Status: COMPLETED
-
Clinical and Health-related Outcome of rFVIIIFc Prophylaxis
NCT04583930 ·Status: UNKNOWN
-
Study Evaluating ReFacto in Hemophilia A
NCT00038909 ·Status: COMPLETED ·Phase: NA
-
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
NCT00189982 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
PF-06741086 Long-term Treatment in Severe Hemophilia
NCT03363321 ·Status: COMPLETED ·Phase: PHASE2
-
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
NCT04456387 ·Status: COMPLETED ·Phase: PHASE3
-
Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies
NCT01608347 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A
NCT02930317 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor
NCT00851721 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
NCT03587116 ·Status: COMPLETED ·Phase: PHASE3